Arexvy RSV vaccine safety data – older adults

Australia’s active vaccine safety system

RSV vaccines

Data on this page show the responses of individuals aged 60 years and older who received an Arexvy respiratory syncytial virus (RSV) vaccine and completed an AusVaxSafety survey sent in the days following vaccination.

These data provide a profile of what to expect in the days following Arexvy RSV vaccination and can assist in planning for vaccination.

Data on this page are updated monthly.

AusVaxSafety's active vaccine safety surveillance system complements the enhanced safety surveillance activities of the Therapeutic Goods Administration (TGA).

Further information on Arexvy RSV vaccine can be found at the links below:

•    Arexvy – Australian Immunisation Handbook
•    Arexvy: Australian prescription medicine decision summary – TGA
•    Respiratory syncytial virus (RSV) immunisation – NCIRS.

Last updated May 2025

RSV vaccines

News & events

All news & events

14 July 2025 | News

Fewer adverse events reported following NIP pneumococcal vaccine change

03 June 2025 | News

New AusVaxSafety data confirms Abrysvo RSV vaccine is well tolerated during pregnancy; adverse events comparable to other maternal vaccinations

18 May 2025 | News

2025 Australian flu season: Who should get a flu shot, which vaccines are available and what to expect in the days following your vaccination

31 March 2025 | News

AusVaxSafety commences routine surveillance of 2025 seasonal influenza vaccines

AusVaxSafety receives funding
from the Australian Government

NCIRS, Kids Research, Sydney Children’s Hospitals Network, Cnr Hawkesbury Rd & Hainsworth St, Westmead Locked Bag 4001, Westmead NSW 2145 Tel (612) 9845 1433 | Fax (612) 9845 1418 | ABN 53 188 579 090

We acknowledge that the National Centre for Immunisation Research and Surveillance (NCIRS) is on the land of the traditional owners the Aboriginal and Torres Strait Islander peoples, the First Australians, and recognise their culture, history, diversity and their deep connection to the land. Together, through research and partnership, we aim to move to a place of equity for all. NCIRS also acknowledges and pays respect to other Aboriginal and Torres Strait Islander nations from which our research, staff and community are drawn.

Our website meets the criteria for credibility and content as defined by the Global Advisory Committee on Vaccine Safety.

We acknowledge that the National Centre for Immunisation Research & Surveillance (NCIRS) is on the land of the traditional owners the Aboriginal and Torres Strait Islander peoples, the First Australians, and recognise their culture, history, diversity and their deep connection to the land. Together, through research and partnership, we aim to move to a place of equity for all. NCIRS also acknowledges and pays respect to other Aboriginal and Torres Strait Islander nations from which our research, staff and community are drawn.

Arexvy RSV vaccine safety data – older adults

RSV vaccines

RSV vaccines

News & events

Fewer adverse events reported following NIP pneumococcal vaccine change

New AusVaxSafety data confirms Abrysvo RSV vaccine is well tolerated during pregnancy; adverse events comparable to other maternal vaccinations

2025 Australian flu season: Who should get a flu shot, which vaccines are available and what to expect in the days following your vaccination

AusVaxSafety commences routine surveillance of 2025 seasonal influenza vaccines

Subscribe to our newsletter for immunisation professionals

Subscribe to our newsletter for immunisation professionals